Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Study on Environmental and GenomeWide predictors of early structural brain Alterations in Young students

SEGWAY

Mounting evidence suggests that early life factors have an important impact on the occurrence of late-life neurological diseases. From a public health perspective this is of particular relevance for dementia, the prevalence of which is increasing drastically, with no available preventive treatment, and epidemiological data suggesting that...

Funding Programme
Start Date
End Date
Total Funding
€ 1 500 000
European Countries Involved

Studying the role of the retrosplenial cortex in flexible learning

REFLEX

An emerging view of cortical area function posits that instead of primarily accounting for sensory processing and motor control, cortical areas might mediate flexible handling of sensory information and motor planning through learning and memory. In this project I propose to investigate this notion focusing on the function of retrosplenial cortex...

Funding Programme
Start Date
End Date
Total Funding
€ 175 420
European Countries Involved

Subjective cognitive decline in preclinical Alzheimer’s Disease: European initiative on harmonization and on a lifestyle-based prevention strategy

EURO-SCD

Subjective cognitive decline (SCD) in elderly individuals with still normal cognitive performance is considered an at-risk condition of Alzheimer's disease (AD) dementia and may reflect its first symptomatic manifestation. This makes SCD a promising target for dementia prevention trials. This project aims at creating a transnational, harmonized...

Funding Programme
Start Date
End Date
Total Funding
€ 834 697
European Countries Involved

Successful caregiver communication and everyday situation support in dementia care

SUCCESS

Due to growing life expectancy and unhealthy lifestyles, dementia is a fast growing chronic disease that affects the behaviour and communication abilities of people living with this neurological disorder. Caregivers are often challenged by this fact, which could lead to stress, helplessness, aggressive situations and caregiver burnout. The SUCCESS...

Funding Programme
Start Date
End Date
Total Funding
€ 1 700 000
European Countries Involved

Super-sensitive detection of Alzheimer’s disease biomarkers in plasma by an innovative droplet split-and-stack approach

SensApp

The detection of biomarkers in body fluids is of great importance for disease early diagnosis. The clinical practice uses typically immunoassay methods (e.g. ELISA, Enzyme-Linked Immuno Sorbent Assay, and related techniques) for biomarker determination. Unfortunately, these techniques fail dramatically in a wide variety of cases where the...

Funding Programme
Start Date
End Date
Total Funding
€ 3 287 563
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Support, Monitoring and Reminder Technology for Mild Dementia

SMART4MD

As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of...

Funding Programme
Start Date
End Date
Total Funding
€ 3 834 555
European Countries Involved

SUstainable PROduction of GALanthamine by both in vitro and agricultural crops of highly galanthamine-containing plants

SUPROGAL

Galanthamine is an alkaloid produced exclusively by plants of the family Amaryllidaceae, mainly belonging to the genus Galanthus, Leucojum and Narcissus. Owing to its acetylcholinesterase inhibitory activity, galanthamine is used and marketed for the treatment of the Alzheimer’s disease, among others. Although it is obtained by organic synthesis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 343 680
European Countries Involved

Synapse-to-nucleus communication in Alzheimer’s disease

STAD

Understanding how fast events at synapses are converted into long-lasting changes of neuronal acti- vity is a very important question in neuroscience. Several recent studies demonstrated that synapses and nuclei are connected by bidirectional communication routes that enable the efficient transfer of information and regulate the long-term...

Funding Programme
Start Date
End Date
Total Funding
€ 838 087
European Countries Involved

Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

SYNAPSING

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimers disease and...

Funding Programme
Start Date
End Date
Total Funding
€ 6 999 921
European Countries Involved

Synaptic circuit protection in Alzheimers’s disease (AD) and Huntingtion’s disease (HD): BDNF/TrkB and Arc signaling as rescue factors

CircProt

Alzheimer´s (AD) and Huntington´s disease (HD) result from the erroneous communication of neurons at synapses in different brain areas (neocortex, hippocampus, striatum). The protein BDNF regulates synaptic communication under healthy conditions. However, insufficient release of BDNF from neurons and defective BDNF signaling in target neurons...

Funding Programme
Start Date
End Date
European Countries Involved

Synaptic Dysfunction in Alzheimer Disease

SyDAD

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between...

Funding Programme
Start Date
End Date
Total Funding
€ 3 846 736
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).